Davide Frumento | Molecular Oncology | Best Researcher Award

Prof. Davide Frumento | Molecular Oncology | Best Researcher Award

Adjunct Professor, RomaTre University, Italy

Dr. Davide Frumento is an experienced academic and researcher currently serving as an adjunct professor at Roma Tre University and Milan University in Italy. With a strong background in chemical engineering and biotechnology, he has contributed extensively to the scientific community in various research fields. His multidisciplinary expertise bridges molecular oncology, epigenetics, and biotechnology. Passionate about advancing scientific knowledge, Dr. Frumento has worked in both academic and industry settings, collaborating with top-tier institutions like Harvard University. His research is focused on innovative solutions in health, biotechnology, and environmental sustainability.

Profile

Orcid

Educationย 

Dr. Davide Frumento holds a PhD in Chemical Engineering from Genoa University (2012-2015), where he specialized in biotechnology applications. He graduated with a BSc and MSc in Biotechnology from the same institution (2005-2011). He further broadened his qualifications with a certification as a Scientific Expert for Criminal Procedures Court of Savona (2024). His academic journey reflects a consistent commitment to advancing his knowledge and skills, particularly in molecular sciences. Throughout his career, Dr. Frumento has continuously expanded his expertise by engaging in postdoctoral research at prominent institutions, including the University of Genoa, Milan University, and Harvard University. His extensive education has laid a strong foundation for his contributions to both academia and the industry.

Experience

Dr. Frumento has a distinguished career in academia and research. Since February 2025, he has served as an adjunct professor at the Penitentiary University Center, Milan University. He also holds a position as an adjunct professor in Epigenetics at Roma Tre University, Italy, since 2021. Previously, he has worked as a postdoctoral researcher at Genoa University, San Raffaele Hospital, and Milan University, where he contributed to research in health sciences and biotechnology. His postdoctoral research has spanned multiple departments, including DISSAL, DIMES, and DIFAR, focusing on various aspects of molecular biology, microbiota, and immunology. Dr. Frumento’s industrial experience includes a role as a Quality Control Microbiology Analyst at Noberasco SpA, further showcasing his diverse professional background. His broad expertise in both academic and industry research makes him a significant contributor to the scientific community.

Awards and Honors

Dr. Frumento’s contributions to the scientific field have earned him several prestigious awards. Notably, in 2021, he received the Smart Cup Scientific Award for Innovation and Technology from Regione Liguria, recognizing his work in health and environmental technology implementation. Earlier, in 2014, he won the Start Cup Scientific Award from the University of Genoa for his innovative work on a microtubular photobioreactor, aimed at improving microalgae culture for commercial use. His dedication to scientific innovation is also reflected in his membership in multiple scientific and technical organizations, including STRA and the Research Data Alliance. Dr. Frumento’s recognition within both the academic and industry sectors highlights his commitment to advancing research in molecular sciences, biotechnology, and environmental sustainability.

Research Focus

Dr. Frumento’s research spans several cutting-edge areas of molecular biology, with particular emphasis on biotechnology, molecular oncology, epigenetics, and environmental sciences. His work on the human microbiota’s role in immune responses and diseases such as hepatitis C and multiple sclerosis has contributed significantly to understanding their interplay. Additionally, he has explored the role of sirtuins in autoimmunity, studying SIRT6 inhibition as a therapeutic strategy for multiple sclerosis and other autoimmune diseases. Dr. Frumentoโ€™s research in the application of light-based technologies in immunotherapy further highlights his focus on innovative solutions for health and disease management. His work extends to environmental sustainability, where he investigates biotechnological applications for waste management and bioengineering, particularly in areas such as microalgae culture. By blending molecular biology with practical applications in medicine and the environment, Dr. Frumento continues to push the boundaries of scientific discovery.

Publication Top Notes

  • Interaction Between Human Microbiota, Immune System, and Hepatitis C Virus Infection: A Narrative Review ๐Ÿฆ 
  • Light-based technologies in immunotherapy: advances, mechanisms, and applications ๐Ÿ’ก
  • Effects of Wildfire Exposure on the Human Immune System ๐Ÿ”ฅ๐Ÿงฌ
  • Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment ๐Ÿ’Š
  • Health Technology Assessment (HTA) sullโ€™introduzione di coorti aggiuntive per la vaccinazione contro il meningococco ๐Ÿฆ ๐Ÿ’‰
  • Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration ๐Ÿง 
  • E-Muser (Enhanced Multiple Sclerosis Expected Rate): A Technical Improvement ๐Ÿง‘โ€๐Ÿ”ฌ
  • Sarcoglycanopathies: A Novel Predictive Approach ๐Ÿงฌ
  • SIRT6 inhibition as a therapeutic approach for treating multiple sclerosis ๐Ÿง ๐Ÿ’‰
  • DAI (Disease Aggressiveness Index) Implementation ๐Ÿ“Š
  • MuSER (Multiple Sclerosis Expected Rate) Predictive Model Development ๐Ÿง ๐Ÿ“ˆ
  • Gut Microbiota Role in Liver Regeneration ๐Ÿฆ ๐Ÿ’ก
  • Microbiota and HCV Infection Interplay ๐Ÿฆ 
  • Oral bacteria contribution in wine flavor perception ๐Ÿท๐Ÿฆ 
  • The efficacy of the new anti HCV therapy, implementation of a path based on the logic of micro-elimination in the Department of Mental Health and Addictions ASL4 Chiavarese ๐Ÿ’Š

 

 

Yousif Kariri | Cancer | Best Researcher Award

Dr Yousif Kariri | Cancer | Best Researcher Award

Assistant Professor ,ย Shaqra University , Saudi Arabia

Dr. Y.A. Kariri is a Saudi researcher and academic, currently an Assistant Professor at Shaqra Universityโ€™s College of Applied Medical Sciences in Saudi Arabia. Born in Jazan on February 11, 1988, he has an extensive academic and professional background spanning multiple countries. He earned a BSc in Clinical Laboratory Science from King Khalid University, an MSc in Medical Laboratory Sciences from RMIT University (Australia), and a PhD in Pathology from the University of Nottingham (UK). Dr. Kariri has expertise in cancer research, particularly in breast cancer, and is an active member of multiple pathology societies. As the Head of Online Learning and Learning Resources at Shaqra University, he has demonstrated leadership in academic administration. He has been instrumental in driving scientific research initiatives and is also an expert in cell culture and data analysis. Dr. Kariri is passionate about integrating advanced research methodologies in education.

Profile

Strengths for the Award

  1. Advanced Educational Qualifications:
    • PhD in Pathology (University of Nottingham, UK, 2022) โ€” This is a high-level qualification and highlights a solid foundation in scientific research.
    • Masterโ€™s and Bachelor’s Degrees โ€” The individual has international experience, having studied in Australia and the UK, further enhancing their research capacity and global perspective.
  2. Relevant and Impactful Research Contributions:
    • Publications in High-Impact Journals:
      • The individual has contributed to several peer-reviewed journal articles in oncology, specifically breast cancer research, with multiple publications in reputable journals like Cancers, Breast Cancer Research and Treatment, and Pathobiology. These contributions are significant, especially the involvement in studies that examine molecular mechanisms of breast cancer and biomarkers in cancer prognosis.
      • Notable publications include research on gene expression, prognostic biomarkers, and lymphovascular invasion, areas critical to advancing cancer diagnostics and treatment.
      • Articles such as “Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer” demonstrate a deep engagement with molecular pathology.
  3. Leadership and Experience in Academia:
    • The individual has held multiple leadership roles at Shaqra University, including Head of Online Learning and Learning Resources and Head of Student Activities, demonstrating the ability to lead teams and enhance educational outcomes.
    • They have also served as an Assistant Professor and have experience in both teaching and curriculum development, particularly in clinical laboratory sciences.
  4. Interdisciplinary Expertise:
    • Expertise in cell culture (in vitro), data analysis (SPSS, PRISM, Cluster analysis), and experience as a medical technologist adds practical knowledge to the research profile, helping bridge the gap between laboratory work and applied medical sciences.
    • Involvement in the Scientific Research Committee and as a publication reviewer in cancer research journals showcases their ability to critically engage with current scientific work and contribute to advancing the field.
  5. International Exposure:
    • Having studied and worked in three different countries (Saudi Arabia, Australia, and the UK), this individual brings a broad, international perspective to their research and teaching, enhancing their academic and professional profile.

Areas for Improvement

  1. Broader Research Collaborations:
    • While the individual has excellent research experience, their publications appear to focus primarily on breast cancer. Exploring broader collaborations in other areas of oncology or interdisciplinary research could further enhance their visibility and impact in the scientific community.
    • Expanding collaborations with international research institutions or leading cancer centers could also broaden the scope and depth of their research, potentially leading to larger-scale, multicentric studies.
  2. Increased Research Grant Applications:
    • The individual’s profile does not mention securing significant research funding or grants. Applying for competitive research grants could enhance the individualโ€™s research capacity and provide more opportunities for large-scale projects, particularly in the area of cancer research.
  3. Further Outreach and Public Engagement:
    • Engaging more with the public or policy-making bodies through science communication efforts, public lectures, or collaborations with healthcare professionals could raise awareness about their research and broaden its impact beyond academia.

Educationย 

Dr. Y.A. Kaririโ€™s educational journey has been both diverse and international. He completed his BSc in Clinical Laboratory Science from King Khalid University (2011), laying the foundation for his career in laboratory sciences. He then pursued an MSc in Medical Laboratory Sciences from the Royal Melbourne Institute of Technology University (RMIT) in Australia (2017), where he honed his skills in molecular biology and pathology. To further his research aspirations, Dr. Kariri earned a PhD in Pathology from the University of Nottingham (UK) in 2022, where his research focused on the molecular mechanisms behind breast cancer and lymphovascular invasion. Alongside his formal education, Dr. Kariri participated in various professional development programs, including a Higher Education Developer Diploma from the University of Nottingham (2022), which enhanced his teaching and academic leadership skills.

Experience

Dr. Y.A. Kariri has a rich blend of academic and research experience. He began his professional journey with a one-year internship at King Fahad Hospital in Jazan (2010-2011), where he gained hands-on experience in clinical laboratory operations. He then pursued an MSc project at RMIT University, focusing on medical laboratory sciences (2017). Since joining Shaqra University in 2017, Dr. Kariri has taken on several significant roles, including Secretary of the Scientific Council (2017-2018). In 2022, he became an Assistant Professor at the College of Applied Medical Sciences, where he continues to teach and conduct research. He has also served as the Head of Online Learning and Learning Resources and Head of Students Activities at Shaqra University (2022โ€“2024). In addition, Dr. Kariri is a member of the Scientific Research Committee and has extensive experience in cell culture and data analysis.

Awards and Honors

Dr. Y.A. Kariri has been the recipient of several prestigious awards and honors, recognizing his academic and research excellence. He was awarded the King Abdullah Scholarship Program (2008-2011) for his masterโ€™s degree, an honor that allowed him to pursue advanced studies at RMIT University in Australia. He was also a PhD Scholar from Shaqra University in Saudi Arabia, enabling his research on breast cancer molecular mechanisms. His international educational background and research contributions have earned him recognition within the academic community. As a researcher, he has been honored with invitations to serve as a publication reviewer for several high-impact journals focusing on oncology and pathology. His leadership roles at Shaqra University, particularly in advancing online learning and student activities, have further cemented his reputation as an influential educator and scholar.

Research Focusย 

Dr. Y.A. Kariri’s research focuses primarily on breast cancer and its molecular mechanisms, with an emphasis on lymphovascular invasion (LVI) and related prognostic biomarkers. His PhD project at the University of Nottingham (UK) explored the molecular genes driving breast cancer and their role in LVI, a key factor in cancer metastasis and poor prognosis. His work has been instrumental in identifying and validating novel biomarkers and gene signatures that could serve as therapeutic targets and predictive indicators for cancer progression. His studies have contributed to the broader understanding of cancer cell migration, gene expression, and the molecular complexity of invasive cancer. Dr. Kariri is skilled in cell culture (in vitro) and advanced data analysis, using tools like SPSS, PRISM, and Cluster Analysis to extract meaningful insights from experimental data. His research continues to bridge the gap between molecular biology and clinical application in cancer therapy.

Publications

  1. The role of the ALKBH5 RNA demethylase in invasive breast cancer ๐Ÿงฌ๐Ÿ”ฌ
  2. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer ๐Ÿ”ฌ๐Ÿ“Š
  3. Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer ๐Ÿงช๐Ÿ“‘
  4. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer ๐Ÿ’‰๐Ÿ“‰
  5. The itim-containing receptor: Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) modulates immune response and confers poor prognosis in invasive breast carcinoma ๐Ÿงซ๐Ÿ’ฅ
  6. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer ๐Ÿงฌ๐Ÿ“ˆ
  7. Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype ๐Ÿ”ฌ๐ŸŒฑ
  8. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer ๐Ÿงฌ๐Ÿ”
  9. Utility of ankyrin 3 as a prognostic marker in androgen-receptorโ€‘positive breast cancer ๐Ÿ”ฌโš–๏ธ
  10. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer ๐Ÿงช๐Ÿงฌ

Conclusion

This individual is undoubtedly a strong candidate for the Best Researcher Award based on their extensive academic background, significant contributions to cancer research, and leadership in higher education. Their research has direct implications for cancer diagnostics, prognosis, and treatment, with a focus on the molecular mechanisms that drive breast cancer, making them highly relevant to current healthcare challenges.Their strengths in academic leadership, combined with their technical expertise in laboratory sciences, make them a well-rounded and capable researcher. However, expanding their research horizons, applying for larger research grants, and further increasing their public engagement could elevate their profile even further.

Sharad Singhal | Cancer Resistance Award | Best Researcher Award

Prof Sharad Singhal | Cancer Resistance Award | Best Researcher Award

Prof Sharad Singhal, Beckman Research Institute of City of Hope , United States

Sharad S. Singhal, Ph.D., born September 12, 1963, in Agra, India, is a Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. He earned his Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Singhal’s research focuses on protein chemistry, drug resistance mechanisms, and the role of RLIP76 in cancer biology. He has received multiple prestigious grants from the Department of Defense for his innovative work in cancer therapeutics.

Publication Profile

Scopus

Education

Sharad S. Singhal completed his undergraduate studies in Chemistry, Zoology, and Botany followed by a Master’s degree in Organic Chemistry from Agra University, India. He earned his Ph.D. in Biochemistry from the Central Drug Research Institute, Lucknow, India, under the supervision of Dr. Chanan Singh. His doctoral research focused on enzyme modulation by macro-ionic interactions, particularly starch-splitting enzymes.

Experienceย 

Dr. Singhal’s academic career includes positions at various esteemed institutions. He served as an Assistant Professor at the University of Texas Medical Branch, Galveston, and later as an Associate Professor at the University of Texas at Arlington. He also held a position as Associate Professor at the University of North Texas Health Science Center before joining City of Hope Comprehensive Cancer Center as a Research Professor.

Awards and Honors

Sharad S. Singhal has been recognized for his contributions to cancer research with awards such as the Junior and Senior Research Fellowships from the Council of Scientific and Industrial Research, India. He has received significant research funding from the Department of Defense, including awards for studies on breast cancer, melanoma, ovarian cancer, and small cell lung cancer. Dr. Singhal’s work has been pivotal in advancing understanding of RLIP76 and its implications in cancer therapy.

Research focus

Dr. Singhal’s research interests lie in protein chemistry, enzymology, and understanding drug resistance mechanisms in cancer cells. His primary focus is on RLIP76, a multi-specific transporter that plays a crucial role in transporting chemotherapeutic drugs and glutathione-electrophile conjugates in mammalian cells. His recent work explores RLIP76 inhibition as a strategy for inducing apoptosis in various cancer types, including melanoma, breast cancer, and ovarian cancer. He employs a multidisciplinary approach combining genetic, molecular, and proteomic techniques to investigate the molecular basis of cancer and develop novel therapeutic strategies.

Publication Top Notes

“Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells” ๐Ÿ“š

“Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC” ๐Ÿ“˜

“Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research” ๐Ÿ“•

“Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies” ๐Ÿ“—

“Emerging biomarkers and molecular targets for precision medicine in cervical cancer” ๐Ÿ“™

“Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers” ๐Ÿ“—